Paclitaxel
| Evidence Level: L5 | Predicted Indications: 71 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Paclitaxel |
| DrugBank ID | DB01229 |
| Brand Names (EU) | Abraxane, Apexelsin, Naveruclif, Pazenir |
| Evidence Level | L5 |
| Predicted Indications | 71 |
| Top Prediction Score | 100.00% |
Approved Indication (EMA)
Apexelsin monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. Apexelsin in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Apexelsin in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | female breast carcinoma | 100.00% | DL |
| 2 | hereditary breast ovarian cancer syndrome | 99.95% | DL |
| 3 | estrogen-receptor negative breast cancer | 99.91% | DL |
| 4 | Ehrlich tumor carcinoma | 99.91% | DL |
| 5 | hormone-resistant breast carcinoma | 99.91% | DL |
| 6 | estrogen-receptor positive breast cancer | 99.91% | DL |
| 7 | bilateral breast carcinoma | 99.89% | DL |
| 8 | breast carcinoma by gene expression profile | 99.89% | DL |
| 9 | nipple carcinoma | 99.89% | DL |
| 10 | ovarian clear cell adenocarcinoma | 99.88% | DL |
| 11 | parameningeal embryonal rhabdomyosarcoma | 99.73% | DL |
| 12 | botryoid-type embryonal rhabdomyosarcoma of the vagina | 99.73% | DL |
| 13 | borderline epithelial tumor of ovary | 99.72% | DL |
| 14 | rhabdomyosarcoma (disease) | 99.72% | DL |
| 15 | embryonal extrahepatic bile duct rhabdomyosarcoma | 99.71% | DL |
| 16 | prostate embryonal rhabdomyosarcoma | 99.69% | DL |
| 17 | maligant granulosa cell tumor of ovary | 99.66% | DL |
| 18 | Ewing sarcoma | 99.66% | DL |
| 19 | extrahepatic bile duct rhabdomyosarcoma | 99.66% | DL |
| 20 | ovarian endometrioid adenocarcinoma | 99.65% | DL |
Showing top 20 of 71 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.